A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.

[1]  M. Urist,et al.  Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. , 1992, Cancer research.

[2]  N. Berger,et al.  Reassessment of patient response to monoclonal antibody 3F8. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Gillies,et al.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.

[4]  S. Gillies,et al.  High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. , 1989, Journal of immunological methods.

[5]  T. Kipps,et al.  Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. , 1989, Cancer research.

[6]  H. Wieland,et al.  Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. , 1989, European journal of biochemistry.

[7]  M. Dyer,et al.  Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. , 1989, Blood.

[8]  N. Berger,et al.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Cheresh,et al.  Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.

[10]  B. Spengler,et al.  Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. , 1973, Cancer research.

[11]  A. Evans,et al.  A proposed staging for children with neuroblastoma. Children's cancer study group A , 1971, Cancer.

[12]  J. Murray,et al.  Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Grizzle,et al.  Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. , 1992, Human antibodies and hybridomas.

[14]  A. Yu,et al.  Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. , 1991, Cancer research.

[15]  R. Handgretinger,et al.  Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells. , 1989, Natural immunity and cell growth regulation.

[16]  F. Berthold,et al.  Bone marrow transplantation in children with neuroblastoma. , 1989, Folia haematologica.

[17]  F. Maul,et al.  MIBG-treatment in neuroblastoma; experiences of the Tübingen/Frankfurt group. , 1988, Progress in clinical and biological research.

[18]  D. Cheresh,et al.  Human tumor antigens. , 1987, Advances in immunology.

[19]  L. Nespoli,et al.  The role of meta-iodo [131I]benzylguanidine (MIBG) in the diagnosis and follow-up of neuroblastoma. , 1986, Pediatric hematology and oncology.